1,864 Shares in Natera, Inc. (NASDAQ:NTRA) Purchased by Institute for Wealth Management LLC.

Institute for Wealth Management LLC. bought a new position in Natera, Inc. (NASDAQ:NTRA - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 1,864 shares of the medical research company's stock, valued at approximately $264,000.

Other institutional investors have also recently made changes to their positions in the company. LRI Investments LLC bought a new position in Natera in the fourth quarter worth $29,000. Rakuten Securities Inc. increased its stake in shares of Natera by 117.8% in the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after acquiring an additional 119 shares in the last quarter. Blue Trust Inc. increased its stake in shares of Natera by 223.7% in the 4th quarter. Blue Trust Inc. now owns 301 shares of the medical research company's stock worth $48,000 after acquiring an additional 208 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of Natera by 372.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after acquiring an additional 261 shares in the last quarter. Finally, Principal Securities Inc. increased its stake in shares of Natera by 20.7% in the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after acquiring an additional 59 shares in the last quarter. Institutional investors own 99.90% of the company's stock.

Insider Buying and Selling at Natera

In related news, CEO Steven Leonard Chapman sold 9,563 shares of the business's stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $138.41, for a total transaction of $1,323,614.83. Following the completion of the sale, the chief executive officer now directly owns 212,541 shares in the company, valued at approximately $29,417,799.81. The trade was a 4.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Solomon Moshkevich sold 3,000 shares of the business's stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $140.48, for a total transaction of $421,440.00. Following the sale, the insider now directly owns 141,782 shares of the company's stock, valued at approximately $19,917,535.36. The trade was a 2.07% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 59,755 shares of company stock worth $8,898,589 in the last three months. 7.60% of the stock is currently owned by company insiders.

Natera Trading Up 0.5%

NASDAQ:NTRA opened at $171.86 on Friday. Natera, Inc. has a 12 month low of $92.14 and a 12 month high of $183.00. The company has a market cap of $23.47 billion, a PE ratio of -116.91 and a beta of 1.74. The company has a 50 day simple moving average of $157.00 and a two-hundred day simple moving average of $158.64.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.09. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The company had revenue of $501.83 million during the quarter, compared to analyst estimates of $446.68 million. During the same quarter in the previous year, the company posted ($0.56) earnings per share. Natera's revenue was up 36.5% compared to the same quarter last year. Research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on NTRA shares. Canaccord Genuity Group reaffirmed a "buy" rating and set a $180.00 target price on shares of Natera in a research note on Wednesday, February 26th. Royal Bank Of Canada initiated coverage on Natera in a research report on Thursday, March 13th. They set an "outperform" rating and a $251.00 price objective for the company. Piper Sandler raised their price objective on Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a research report on Thursday, May 15th. UBS Group raised their price target on Natera from $211.00 to $218.00 and gave the company a "buy" rating in a report on Friday, May 9th. Finally, Wall Street Zen downgraded Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. One investment analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $184.63.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.